Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;184(1):72-81.
doi: 10.1111/bjh.15640. Epub 2018 Nov 20.

Current considerations in AYA Hodgkin lymphoma

Jennifer L Crombie  1 , Ann S LaCasce  1
Affiliations
Review

Current considerations in AYA Hodgkin lymphoma

Jennifer L Crombie et al. Br J Haematol. 2019 Jan.

Abstract

Hodgkin lymphoma (HL) commonly occurs in adolescents and young adults (AYA), defined by the National Cancer Institute as people diagnosed with cancer between the ages of 15 and 39 years. Despite therapeutic advances, the AYA population has derived less incremental benefit compared to both paediatric and adult counterparts. Although the exact aetiology is unclear, contributing factors probably include differences in disease biology, delayed diagnosis, decreased participation in clinical trials and treatment adherence secondary to complex social factors. As such, while HL remains highly curable, there is not a clear consensus regarding the management of patients within this age range, specifically whether paediatric or adult regimens are preferred or how best to incorporate emerging therapeutic advancements. Ongoing clinical trials, as well as continued collaborative efforts are required to address the needs of this population, investigate the potential for unique biological factors and allow for optimization of treatment. Here we review current prognostic and treatment strategies for paediatric and adult patients with HL and highlight complexities around the management of this patient population.

Keywords: AYA; Hodgkin lymphoma; adolescent; lymphoma; young adult.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Distribution of HL subtypes by age. Adapted with permission from: Hochberg, J., Waxman, I.M., Kelly, K.M., Morris, E. & Cairo, M.S. (2009) Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.
See this image and copyright information in PMC

References

    1. Ansell SM (2016) Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol, 91, 434–442. - PubMed
    1. Barr RD, Ferrari A, Ries L, Whelan J & Bleyer WA (2016) Cancer in Adolescents and Young Adults: A Narrative Review of the Current Status and a View of the Future. JAMA Pediatr, 170, 495–501. - PubMed
    1. Bleyer A (2007) Adolescent and young adult (AYA) oncology: the first A. Pediatr Hematol Oncol, 24, 325–336. - PubMed
    1. Bleyer WA (2002) Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol, 38, 1–10. - PubMed
    1. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Huttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kuhnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M & Engert A (2018) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390, 2790–2802. - PubMed